The Traders Daily Report: (OTCBB: SPKL), (OTCBB: FLXT), (OTCBB: CONX), (OTCBB: HPLF), (AMEX: EPM) .
If you enjoy investing in the restaurant sector or if you just enjoy eating good food, then you will want to watch the Spicy Pickle Stockumentary™, located at www.stockwire.com .
----------------------------------------------------------
Chat real-time with other investors about this SPKL news release, by clicking this link: http://www.stockwire.com/SPKL
To view in-depth research, click the following link: http://www.stockwire.com/detailed/analysis.php?company=SPKL
Spicy Pickle Franchising Inc. (OTCBB: SPKL)
On Sunday, September 23, 2007, The Stockwire Group released the much anticipated Spicy Pickle Stockumentary to rave reviews.
Spicy Pickle is one of
In short, the company has grown from twenty franchises to nearly one hundred in two short years, with plenty of upside to come. The company is also led by a man named Marc Geman, who is the same CEO who bought the Pretzel Maker franchise and built it from seven stores to 250 and then sold it to Misses Fields Cookies in 1998.
COMPANY NEWS:
Spicy Pickle(R) fast casual restaurants (OTC Bulletin Board: SPKL) today announced the commencement of public trading for its common stock on the Over The Counter Bulletin Board (OTC BB) quotation medium. The company completed its own self underwritten Initial Public Offering, and the stock recently opened for trading.
Empire Financial Group Inc. (http://www.empirefinancialgroup.com) of
Spicy Pickle, a fast casual franchise concept, has been experiencing significant growth. To date there are 26 units open in nine different states. The restaurants differentiate themselves through a culinary-inspired menu of panini, sub sandwiches, Pizzetti Neapolitan thin-crust pizzas, salads, soups and other items, served in a casual neighborhood setting. Spicy Pickle also offers a range of catering and takeout services.
"Spicy Pickle's IPO is an appropriate step at this point in time, given the company's growth curve and success to date," said Marc Geman, President and CEO of Spicy Pickle Inc. "Since our inception in 1999, Spicy Pickle has evolved from a one-store operation in Denver to a chain of restaurants known from coast to coast for its fresh, healthy and innovative approach to lunch and dinner. The capital raised through our public offering will help maintain this unique positioning. We chose to go public at this time to allow investor participation and more efficient access to financing sources as we seek appropriate sources of capital to fuel our growth."
By the end of 2007, Spicy Pickle anticipates opening approximately 14 more units, bringing its network to 40 restaurants in 13 states. Nearly 50 franchise development agreements have also been signed.
In addition to its franchise activity, Spicy Pickle currently has a breakfast menu in test, potentially opening a new daypart for the chain. The company is also in the process of building a major commissary in
To view this incredible Stockumentary™, visit: www.stockwire.com .
About Spicy Pickle Franchising Inc.
Spicy Pickle restaurants serve high quality meats and fine Italian artisan breads, along with a wide choice of ten different cheeses, twenty-one different toppings, and fifteen proprietary spreads to create healthy and delicious panini and sub sandwiches with flavors from around the world. There are over 150,000 delicious sandwich combinations for you to create, along with eight specialty panini sandwiches that have become favorites of our customers. We also boast the world’s best spicy pickle. Spicy Pickle serves the fast growing “fast casual” market where customers demand more than “fast food,” but without the price point of “casual dining”. The hallmark of a Spicy Pickle restaurant is quality, service and an enjoyable atmosphere. Order at the counter, take a seat, enjoy the fun and relaxed atmosphere, and let the staff do what they do best, service.
----------------------------------------------------------
Chat real-time with other investors about this FLXT news release, by clicking this link: http://www.stockwire.com/FLXT
To view in-depth research, click the following link: http://www.stockwire.com/detailed/analysis.php?company=FLXT
Flexpoint Sensor Systems, Inc. (OTCBB: FLXT)
Flexpoint Sensor Systems, Inc. closed at $1.03 Tuesday, trading 14,200 shares.
Company News- September 26, 2007 Flexpoint Details Automotive Contract
Flexpoint Sensor Systems, Inc. (OTCBB: FLXT) commented earlier today on the previously announced agreement with Intertek Industries Corp. Revenue from the development fees and the initial purchase order are estimated to exceed $100,000 and will impact both the third and fourth quarters.
The Protek Passenger Awareness System is designed to enhance the safety of passengers and personnel in Emergency vehicles. The system provides data to both drivers and administrators concerning the seated positions and securement of passengers and personnel at all times, with the ability to record and monitor data in the event of an accident, or for training purposes.
By utilizing the innovative Bend Sensor technology, the Protek Passenger Awareness System becomes a "smart" device in that it detects if and when EMT's and other rear occupants are seated and secured by location, to ensure their safety. This safety information is immediately available to the driver through a visual display panel with separate indicators for seated' and secured' status for each passenger in a designated position. The Awareness System consists of one control unit and as many seat sensors and seatbelts as required, which on average will be four Bend Sensors per control unit.
Intertek Industrial Corp., located in
"The Protek Passenger Awareness System we have developed with Flexpoint is unmatched in the industry and has the potential to prevent injuries and deaths," stated Scott Bradley, Vice President of Intertek. "We selected the Bend Sensor technology because of its accuracy and reliability and know this technology will be very well received among our existing client base and throughout the industry." "We are pleased with this automotive contract and initial order which showcases our proprietary sensor technology," commented Flexpoint's V.P. of Sales and Marketing Byron Allen. "We recognize this is a specific automotive application for the company's technology and is only one of many applications we are currently developing for this industry. The greater significance of this contract is Flexpoint returning to production and the validation of our technology in the automotive industry." www.intertekindustrial.com
About Flexpoint Sensor Systems, Inc.
Manufactures a patented cutting edge flexible sensor, that has also proven to be an extremely durable switch. The single layer Bend Sensor product allows for the measurement of mechanical movement, air flow, water flow or even vibration. It can be used as a range of motion sensor, or as a durable, & reliable switch in most harsh environments. Flexpoint serves numerous industries including automotive, medical, industrial controls & more.
----------------------------------------------------------
Chat real-time with other investors about this CONX news release, by clicking this link: http://www.stockwire.com/CONX
To view in-depth research, click the following link: http://www.stockwire.com/detailed/analysis.php?company=CONX
Corgenix Medical Corporation (OTCBB: CONX)
Corgenix Medical Corporation closed at $0.42 Tuesday, trading 131,316 shares.
Company News- September 26, 2007 Corgenix to Exhibit New AspirinWorks Test at AAFP 2007 Meeting in
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, announced earlier today it will be exhibiting its new AspirinWorks Test Kit at the American Academy of Family Physicians (AAFP) 2007 Annual Scientific Assembly. The exhibit takes place October 4 - 6 at
The AspirinWorks test was launched nationwide in June 2007 following FDA 510(k) clearance. The test measures the effect of aspirin on platelets through direct measurement of thromboxane production (aspirin's target). The stickier the blood platelets, the less impact the aspirin is having. This crucial information allows physicians to individualize a patient's therapy.
Unlike other platelet tests, which require freshly drawn blood that must be evaluated within at least 4 hours, the AspirinWorks test only requires a urine sample that can be obtained in any doctor's office or patient service center, making the test easy for both physician and patient.
"This conference gives us a chance to meet face to face with physicians who are on the front line in American health care," said Corgenix' Clinical Affairs Director Gordon Ens. "With AspirinWorks now available to virtually every physician in the U.S., this is a tremendous opportunity to educate the physicians in the value of the information that the AspirinWorks product provides and how the test results can affect treatment decisions." Corgenix representatives will be on-hand during AAFP 2007 in booth #1482 to answer questions about Corgenix' full line of diagnostic tests as well as AspirinWorks, including availability of the test, the latest supporting clinical data and how to order the test.
The AspirinWorks Test Kit is an enzyme-linked immunoassay (ELISA) to determine levels of 11 Dehydro Thromboxane B2 (11dhTxB2) in human urine, which aids in the qualitative detection of aspirin effect in apparently healthy individuals post ingestion.
Physicians and laboratories interested in ordering the test can call 800-729-5661, ext. 180, or e-mail info@aspirinworks.com. More information is also available at www.aspirinworks.com.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.
----------------------------------------------------------
Chat real-time with other investors about this HPLF news release, by clicking this link: http://www.stockwire.com/HPLF
To view in-depth research, click the following link: http://www.stockwire.com/detailed/analysis.php?company=HPLF
HepaLife Technologies, Inc. (OTCBB: HPLF)
HepaLife Technologies, Inc. closed at $0.72 Tuesday, trading 41,195 shares.
Company News- September 26, 2007 HepaLife Releases Positive New Research Results for First-of-Its-Kind Bioartificial Liver
HepaLife Technologies, Inc. (OTCBB: HPLF), developer of the first-of-its-kind artificial liver device, earlier today announced significant early results of new in-vitro studies involving the Company's patented PICM-19 liver stem cells, which were placed inside its proprietary artificial liver device and were able to favorably produce urea and successfully remove ammonia, a highly toxic by-product which causes brain damage, coma, and even death.
"Today's results demonstrate that, while inside our bioartificial liver device, HepaLife's PICM-19 cells are able to produce substantial amounts of urea and remove toxic ammonia, while remaining healthy, and replicating important liver-like functions," stated Mr. Frank Menzler, President and CEO of HepaLife. "This is a significant achievement that marks a major milestone in the development of our artificial liver device.
"These new results have certainly exceeded our early performance expectations of the HepaLife bioartificial liver design. Our goal is to now further evaluate the HepaLife bioartificial liver system in-vitro and in-vivo, and continue to move closer to an application with the Food and Drug Administration for our cell-based device." According to researchers, the most vital component in an artificial liver device is not the mechanical hardware, but rather, it is the biological cells inside the device which are responsible for truly replicating and performing the functions of the human liver, similar to the functions mimicked by HepaLife's PICM-19 cells in today's research outcomes.
Research data from experiments of the PICM-19 cells inside HepaLife's artificial liver device indicates that the system removed toxic ammonia, and successfully produced significant amounts urea and liver-specific protein such as albumin over the entire duration of the study. Most importantly, the production of urea and albumin increased over time, reaching peak levels at termination of the study after two weeks.
In observations of cell replication and growth, researchers confirmed earlier findings where PICM-19 liver cells remained contact-inhibited, an important indicator of normal cell growth, since cells which are not contact-inhibited tend to become cancerous. In contrast, HepaLife's PICM-19 cells inside its liver device system did not develop tumors or become cancerous, but rather, remained non-tumorigenic.
In the same tests, HepaLife's PICM-19 liver stem cells successfully differentiated into hepatocytes (liver cells) displaying normal morphology, an indication of the cells' physical form and structure.
In evaluating the chemical function and overall health of the PICM-19 liver cells inside HepaLife's bioartificial liver system, researchers analyzed levels of lactate and glucose -- indicators of metabolic function -- alongside oxygen and carbon dioxide, respectively. In all cases, these monitored levels remained favorably within targeted parameters throughout the duration of the studies.
"These results suggest that HepaLife's bioartificial liver system is an artificially created, living biosystem' -- our goal from the early beginning -- with cells that behave as we have long desired for our artificial liver device," concluded Mr. Menzler.
Intended for the treatment of liver failure, the HepaLife Bioartificial Liver device consists of three basic components: (1) a plasma filter, separating the patient's blood into blood plasma and blood cells; (2) the bioreactor, a unit filled with PICM-19 cells which biologically mimic the liver's function; and (3), the HepaDrive, a perfusion system for pumping the patient's plasma through the bioreactor while controlling gas supply and temperature for best possible performance of the cells.
Incorporating the PICM-19 cell line, HepaLife is developing the first-of-its-kind bioartificial liver. HepaLife's bioartificial liver currently under development is designed to operate outside the patient's body. The bioartificial liver is envisioned to mimic important functions of the human liver by circulating the patient's blood inside the device, where it is exposed to HepaLife's patented PICM-19 liver stem cells, thus processing the patient's blood-plasma by removing toxins, enhancing metabolic function, and ultimately, imitating the liver's natural function.
ABOUT HEPALIFE TECHNOLOGIES, INC.
HepaLife Technologies, Inc. (OTCBB: HPLF) is a developer of cell-based medical technologies addressing prevalent human health concerns.
Current cell-based technologies under development by HepaLife include 1) the first-of-its-kind artificial liver device, 2) proprietary in-vitro toxicology and pre-clinical drug testing platforms, and 3) novel cell-culture based vaccine production methods for the manufacture of vaccines against H5N1 avian influenza and other viruses.
----------------------------------------------------------
Chat real-time with other investors about this EPM news release, by clicking this link: http://www.stockwire.com/EPM
To view in-depth research, click the following link: http://www.stockwire.com/detailed/analysis.php?company=EPM
Evolution Petroleum Corporation (AMEX: EPM)
Evolution Petroleum Corporation closed at $2.83 Tuesday, trading 31,600 shares.
Company News- September 26, 2007 Evolution Petroleum Corporation Announces Participation at IPAA Oil & Gas Investment Symposium
Evolution Petroleum Corporation (AMEX: EPM) announced earlier today that the company will participate in the IPAA Oil & Gas Investment Symposium being held on October 1 - 3, 2007 at the Palace Hotel in San Francisco. Mr. Robert Herlin and Mr. Sterling McDonald, the company's CEO and CFO, respectively, will host breakfast on Tuesday and Wednesday, October 2nd and 3rd, and Mr. McDonald will present to the attendees on Wednesday, October 3 at 4:20 p.m. Pacific Time (7:20 p.m. Eastern).
Interested parties can access the IPAA presentation during a live webcast via the following link: http://www.vcall.com/IC/CEPage.asp?ID=121100. Additional conference information and a link to the webcast of Mr. McDonald's presentation can be found at www.ipaa.org.
A link to the webcast and a copy of the presentation will also be available on the Company's website at www.evolutionpetroleum.com.
About Evolution Petroleum
Evolution Petroleum Corporation (http://www.evolutionpetroleum.com) acquires mature, onshore oil and gas resources and applies conventional and specialized technology to accelerate production and develop incremental reserves and value. The Company focuses on initiatives in EOR, Bypassed Resources and Unconventional Gas development. Principal assets of the Company include 7.4% in overriding royalty interests and a 25% reversionary working interest in the 13,636 acre Delhi Field Holt Bryant Unit in northeast
----------------------------------------------------------
About Stockwire:
Stockwire is a company that is pioneering a new way to research companies before you invest them. It's called a Stockumentary. A Stockumentary is a documentary on a publicly traded company. Imagine a Dateline NBC segment, but on a publicly traded company. We are the first company to ever bring this type of quality research to investors in this format.
The Stockumentary has video interviews with management, product demos, video tours of office or factory, research reports, sec filings and much more. All of this is delivered to investors in high quality video, either by mail or email.
Stockwire.com is owned by Stockwire Research Group Inc. (SRGI) and is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies.
As detailed below, this publication accepts compensation from some of the companies from which it features. To the degrees listed herein, this Newsletter should not be regarded as an independent publication. All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the Newsletter is neither an offer nor solicitation to buy or sell any securities mentioned.
While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.
We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the National Association of Securities Dealers ("NASD") at www.nasd.com. The NASD has published information on how to invest carefully at its web site.
Readers can review all public filings by companies at the SEC's EDGAR page. www.sec.gov/edgar.shtml
Stockwire.com is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. Stockwire.com is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible.
From time to time SRGI sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.
Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features on Stockwire.com. Likewise, Stockwire.com is owned by Stockwire Research Group Inc. (SRGI). To the degrees enumerated herein, this newsletter and website should not be regarded as an independent publication.
All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company on Stockwire.com is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.
The editor, members of the editor's family, and/or entities with which the editor is affiliated aside from Stockwire Research Group Inc. (SRGI) itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF STOCKWIRE.COM.
We often accept restricted shares of company stock; by SEC regulations, restricted shares cannot be sold into the market for a period of at least one year from the time that the shares are issued. In such cases, we detail in the Disclaimer the specific term of any restrictions. We also receive compensation in the form of stock options, in which case we receive the right to buy shares of the stock of the company at issue, at a specified time and a specified price. In such circumstances, we specify on our Disclaimer the terms of the options received. On occasion, we also accept free-trading shares in a company that we cover. However, by policy we generally do not buy or sell any shares of a company's stock within three trading days after any such company's profile, commentary, or other company-specific information is disseminated on Stockwire.com Web site. In cases where we do trade within the three day window, our volume will never represent more than 5% of the daily volume, thereby minimizing any effect we could have on the potential price movement.
While our policies as detailed above are designed to minimize any impact upon our members of a conflict of interest between our company and our members, each member should be fully aware that such potential and actual conflicts of interest may well exist due to the compensation structure detailed herein. For this reason, and because the information contained on Stockwire.com is updated on a regular basis as circumstances change, each member is strongly encouraged to periodically review the Profile Compensation section at http://www.stockwire.com/disclaimer_profiles.htm .
The Stockwire Group .
512.358.8440 .
info@stockwire.com .
